论文部分内容阅读
目的探讨辛伐他汀对无冠心病的高胆固醇血症患者超敏C反应蛋白(hs-CRP)和细胞间黏附分子-1(ICAM-1)含量的影响。方法 51例高胆固醇血症患者应用辛伐他汀20 mg/d,每晚顿服,治疗12周,分别在治疗前、治疗12周后测定患者的血脂指标、hs-CRP和ICAM-1。结果辛伐他汀治疗后,患者总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平([5.06±0.99)、(3.21±1.02)mmol/L]较治疗前[分别为(5.69±0.96)、(3.58±1.03)mmol/L]明显下降,差异均有统计学意义(P<0.01,P<0.05);与治疗前[hs-CRP、ICAM-1分别为(3.36±0.47)mg/L、(1.42±0.56)ng/ml]相比,治疗后,hs-CRP和ICAM-1水平[分别为(1.56±0.22)mg/L、(1.18±0.16)ng/ml]较治疗前明显降低,差异均有统计学意义(P<0.05)。结论辛伐他汀可明显改善无冠心病的高胆固醇血症患者血浆hs-CRP和ICAM-1的含量。
Objective To investigate the effects of simvastatin on the levels of hs-CRP and ICAM-1 in patients with hypercholesterolemia without coronary heart disease. Methods Fifty-one patients with hypercholesterolemia were treated with simvastatin 20 mg once daily for 12 weeks. Lipid levels, hs-CRP and ICAM-1 were measured before treatment and after 12 weeks of treatment. Results After treatment with simvastatin, the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) were significantly higher than those before treatment [5.66 ± 0.99 and 3.21 ± 1.02 mmol / L, 0.36), (3.58 ± 1.03) mmol / L], the differences were statistically significant (P <0.01, P <0.05). Compared with those before treatment [hs-CRP and ICAM-1 were (3.36 ± 0.47) mg (1.56 ± 0.22) mg / L, (1.18 ± 0.16) ng / ml, respectively] compared with those before treatment (1.42 ± 0.56ng / ml) Was significantly lower, the difference was statistically significant (P <0.05). Conclusion Simvastatin can significantly improve the plasma hs-CRP and ICAM-1 levels in patients with hypercholesterolemia without coronary heart disease.